Establishment and Characterization of 10 Human Pancreatic Cancer Cell Lines Including a HER2 Overexpressed Cell Line.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
Historique:
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
22
9
2020
Statut:
ppublish
Résumé
The incidence of pancreatic adenocarcinoma (PA) approximates its prevalence, as the malignancy is almost consistently fatal within a year. Although the currently available adjuvant therapy seems to provide survival benefit, it is only moderate, and the standard regimen has not yet been established. Therefore, more biological resources to investigate the PA are needed. Here, we established and characterized 10 human pancreatic cancer cell lines derived from primary tumor mass. Whole exome sequencing technique was used to identify driver mutations and aberrant pathways in each cell line. Five anticancer drugs were treated to find half maximal effective concentration (EC50), and the response was analyzed in reference to mutational status. Frame shift mutations in ARID1A gene and HER2 amplification were mutually related to better response to the anticancer drugs. In contrast, frame shift mutation in MSH6 gene was associated with resistance to anticancer drugs. In summary, we established 10 pancreatic cancer cell lines and integrated various molecular aberrations and features of pancreatic cancer cells. Our biological resources are expected to contribute to facilitating research on PA.
Identifiants
pubmed: 31688591
doi: 10.1097/MPA.0000000000001420
pii: 00006676-201911000-00010
pmc: PMC6867661
doi:
Substances chimiques
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1285-1293Références
Oncotarget. 2015 Mar 10;6(7):4553-61
pubmed: 25714017
Cancer Lett. 2016 Oct 10;381(1):194-200
pubmed: 26571462
Cell Tissue Res. 2002 May;308(2):205-14
pubmed: 12037578
Am J Pathol. 2002 Jan;160(1):91-9
pubmed: 11786403
Transl Oncol. 2018 Oct;11(5):1232-1243
pubmed: 30114595
Cancer J. 2012 Nov-Dec;18(6):492-501
pubmed: 23187835
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Neoplasia. 2012 Feb;14(2):121-30
pubmed: 22431920
Clin Cancer Res. 2002 Aug;8(8):2536-40
pubmed: 12171881
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Br J Cancer. 2005 Apr 25;92(8):1372-81
pubmed: 15812554
Pancreas. 2009 Mar;38(2):184-96
pubmed: 19002021
Cancer Res. 1989 Sep 1;49(17):4682-9
pubmed: 2547513
World J Gastrointest Oncol. 2015 Oct 15;7(10):250-8
pubmed: 26483879
Br J Cancer. 1999 Apr;80(1-2):11-6
pubmed: 10389971
Genome Med. 2013 Aug 31;5(8):78
pubmed: 24004612
PLoS One. 2012;7(9):e46002
pubmed: 23029359
J Surg Oncol. 2013 Jan;107(1):1-7
pubmed: 22589078
Nature. 2015 Feb 26;518(7540):495-501
pubmed: 25719666
Pol J Pathol. 2003;54(1):31-7
pubmed: 12817878
Hematol Oncol Clin North Am. 2015 Aug;29(4):595-608
pubmed: 26226899
Nat Protoc. 2006;1(5):2315-9
pubmed: 17406473
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
pubmed: 20952405
Dig Dis. 2010;28(4-5):645-56
pubmed: 21088417
Cell Rep. 2015 Apr 28;11(4):564-76
pubmed: 25892239
Trends Biotechnol. 2013 Jun;31(6):347-54
pubmed: 23597659
Eur J Hum Genet. 2011 Apr;19(4):472-8
pubmed: 21150883
Lancet. 2001 Nov 10;358(9293):1576-85
pubmed: 11716884
Am J Pathol. 1998 Jun;152(6):1501-7
pubmed: 9626054
Ann Oncol. 2010 Jan;21(1):98-103
pubmed: 19889608
Clin Cancer Res. 2007 Jul 1;13(13):3831-9
pubmed: 17606714
JAMA. 2007 Jan 17;297(3):267-77
pubmed: 17227978
Cancer Res. 2001 Apr 1;61(7):3139-44
pubmed: 11306499